TransCode Therapeutics's total assets for Q3 2024 were $3.94M, a decrease of -18.42% from the previous quarter. RNAZ total liabilities were $2.28M for the fiscal quarter, a -34.79% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.